Curated News
By: NewsRamp Editorial Staff
April 22, 2026
BioElectronics Launches Drug-Free ActiPatch Pain Therapy in Taiwan
TLDR
- BioElectronics Corporation gains market advantage in Taiwan through Aphrodite Medical Group's distribution network, expanding access to its drug-free ActiPatch pain therapy.
- ActiPatch delivers FDA-cleared pulsed shortwave therapy for up to 720 hours, modulating pain at the peripheral nerve level through a non-invasive, wearable device.
- This drug-free pain therapy provides safer alternatives to pharmaceuticals, improving patient quality of life and reducing dependency on traditional pain medications.
- A wearable device that provides continuous pain relief during sleep challenges conventional pain management with innovative bioelectronic technology.
Impact - Why it Matters
This news matters because it represents a significant advancement in global pain management, offering patients a non-invasive, drug-free alternative to traditional pharmaceuticals. With opioid crises and medication side effects being major concerns worldwide, technologies like ActiPatch provide safer options for chronic pain sufferers. The expansion into Taiwan signals growing international acceptance of bioelectronic therapies, potentially reducing healthcare costs and improving quality of life for millions. As populations age and pain management needs increase, such innovations could transform standard care protocols and offer sustainable solutions beyond medication dependency.
Summary
BioElectronics Corporation, a pioneering medical device company specializing in bioelectronic pain therapy, has announced the imminent commercial launch of its flagship product ActiPatch® in Taiwan through a strategic partnership with Aphrodite Medical Group. This expansion marks a significant step in bringing drug-free pain management solutions to the Asian market, leveraging Aphrodite Medical Group's established clinical network and expertise in healthcare delivery. The collaboration positions ActiPatch® to address the growing demand for non-pharmaceutical alternatives in pain treatment, with initial shipments already completed and a coordinated market rollout planned for Q2 2026.
The core of this news revolves around ActiPatch®, a US FDA-cleared medical device that delivers pulsed shortwave therapy to modulate pain at the peripheral nerve level. Each device offers up to 720 hours of continuous therapy, is designed for extended wear including during sleep, and provides a practical, patient-friendly alternative to traditional pharmaceuticals. Key players include Kelly Whelan, CEO of BioElectronics Corporation, who emphasized the strong commercial foundation this partnership establishes, and Yang Pei-Hsien, Vice President of Aphrodite Medical Group, who highlighted the alignment with Taiwan's demand for safe, effective pain management options. The initial focus will be on musculoskeletal pain management, with potential for expansion into other clinical applications over time.
This launch reinforces BioElectronics' strategy of expanding through high-quality distribution partnerships in key markets while maintaining focus on clinically validated, scalable bioelectronic therapies. The original release on www.newmediawire.com provides additional context about both companies: BioElectronics Corporation (OTC: BIEL) develops and commercializes bioelectronic therapies like ActiPatch® and RecoveryRx®, while Aphrodite Medical Group is a Taiwan-based healthcare organization offering comprehensive medical and wellness services. This move not only introduces innovative technology to Taiwan but also challenges traditional pain management paradigms with drug-free innovation, as detailed in the news release.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BioElectronics Launches Drug-Free ActiPatch Pain Therapy in Taiwan
